Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.01.02.008; 17.02.04.008; 24.06.02.012--
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006--Not Available
Tension19.06.02.005--Not Available
Throat irritation07.05.03.004; 22.02.05.013--Not Available
Thrombocytopenic purpura01.08.01.003; 23.06.01.007--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual field defect06.02.07.003; 17.17.01.001--Not Available
Visual impairment06.02.06.008--Not Available
Vital dye staining cornea present13.07.04.010--Not Available
Vitreous detachment06.09.01.002; 12.01.04.005--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Eyelid irritation06.04.04.007; 23.03.04.023--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Cystoid macular oedema06.04.06.010; 12.02.02.005--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Eyelid pain06.08.03.014; 23.03.03.036--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages